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Hepatitis C virus (HCV) causes acute and chronic liver disease in humans, including chronic
hepatitis, cirrhosis, and hepatocellular carcinoma. The polyprotein encoded in the HCV
genome is co- and post-translationally processed by host and viral peptidases, generating the
structural proteins Core, E1, E2, and p7, and five nonstructural proteins. The two envelope
proteins E1 and E2 are heavily glycosylated. Studying the glycan moieties attached to the
envelope E2 glycoprotein is important because the N-linked glycans on E2 envelope protein
are involved in the interaction with some human neutralizing antibodies, and may also have
a direct or indirect effect on protein folding. In the present study, we report the mass
spectrometric characterization of the glycan moieties attached to the E2 glycoprotein. The
mass spectrometric analysis clearly identified the nature, composition, and microhetero-
geneity of the sugars attached to the E2 glycopeptides. All 11 sites of glycosylation on E2
protein were characterized, and the majority of these sites proved to be occupied by high
mannose glycans. However, complex type oligosaccharides, which have not been previ-
ously identified, were exclusively observed at two N-linked sites, and their identity and
heterogeneity were determined. (J Am Soc Mass Spectrom 2008, 19, 428 – 444) © 2008
American Society for Mass SpectrometryHCV infects over 170 million people worldwide.Infection develops into chronic hepatitis, which isone of the most prevalent causes of liver
cirrhosis and represents the most frequent indication for
liver transplantation. HCV is a small, enveloped positive-
strand RNA virus belonging to the Flaviviridae family [1].
The genome of HCV is 9.5 kb, encoding for a single
polyprotein between 3010 and 3033 amino acids long. A
combination of host and viral peptidases are involved in
processing the polyprotein, which results in at least nine
different proteins. The HCV polyprotein is synthesized on
the endoplasmic reticulum (ER) associated ribosomes a n d
is processed co- and post-translationally generating the
structural proteins Core, E1, E2, and p7, and five
nonstructural proteins [2]. The two envelope proteins
E1 and E2 are heavily N-glycosylated and are believed
to be Type 1 transmembrane protein with N terminal
ectodomains and C-terminal hydrophobic anchors [3].
Together, they are expected to form the viral envelope
[4]. During their synthesis, the ectodomains of HCV
glycoproteins are targeted to the ER lumen, where they
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doi:10.1016/j.jasms.2007.11.022are modified by N-linked glycosylation. This suggests
that HCV glycoprotein complexes contain a retention
signal for localization in an intracellular compartment
[5]. These glycoproteins interact to form a noncovalent
heterodimeric complex that accumulates in ER-like
structures. In principle, ER localization of a protein can
be the consequence of actual retention in this organelle
or of retrieval from the Golgi [6, 7].
Glycans have been shown to be essential for proper
functioning of a protein and, therefore, may play a
significant biological role including locating a protein
within the cell, protection of the protein against proteo-
lytic attack, induction and maintenance of the spatial
conformation in a biologically active form, facilitation
of the extracellular secretion as well as direction and
modulation of the immune response [8]. A consensus
sequence for N-glycosylation has been reported, Asn-
Xaa-Ser/Thr/Cys, in which Xaa may be any amino acid
except Pro [9, 10]. One glycosylation site on a protein
may have multiple glycan structures (microheterogene-
ity), and one protein may have different structures at
different sites (macroheterogeneity). Structural hetero-
geneity is an important characteristic of oligosaccha-
rides and significantly complicates the structural anal-
ysis of glycoproteins.
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429J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINPrevious studies have shown that the HCV envelope
proteins are highly modified by N-linked glycans [11–14].
It was reported that E1 has up to six glycosylation sites in
comparison with E2, which has 11 potential glycosylation
sites [15]. A global sequence analysis of the potential
glycosylation sites in E2 indicated that nine of the 11
sites are strongly conserved. The two remaining sites
N94 (N476)* and N158 (N540) showed a level of con-
servation of 75 and 89%, respectively, [* the numbers
correspond to the amino acid sequence of HCV E2
protein, amino acids 1–333 (383–715) from strain HCV-
1a. The positions of the residue are indicated corre-
sponding to the positions in the HCV polyprotein of
reference strain H (GenBank access number AF009606)].
Expression of HCV glycoprotein E2 followed by total
or partial deglycosylation indicates that a large number
of the glycosylation sites are occupied [15]. Previous
studies indicated that some of the N-linked glycans on
E2 protein mediate their recognition by human neutral-
izing antibodies [16]. Furthermore, N-linked glycans
are known to play a role in protein folding, and this
effect can be either direct or indirect [8, 17]. The
presence of a large polar sugar moiety is thought to
affect the folding at least locally, by orienting polypep-
tide segments towards the surface of protein domains.
The major types of N-glycans attached to glycoproteins
are: (1) high mannose, consisting primarily of mannose
(Man) with a maximum number of nine mannoses possi-
ble unless not fully processed, (2) complex type glycans,
mainly composed of N-acetylglucosamine (GlcNAc),
and galactose (Gal) with or without sialic acid, where a
fucose (Fuc) may be added to the first GlcNAc in the
core (Figure 1a), and (3) hybrid type glycans, which are
composed of mannose, GlcNAc-Gal, and with or with-
out sialic acid. There have been several reports about
the glycan types attached to the E2 protein. Most of
them reported that the glycans are only high mannose
type oligosaccharides [5]. It is believed that the lack of
complex type glycosylation on the E2 protein excludes
the step involving the transit through the medial Golgi
and it has been confirmed by immunofluorescence that
HCV glycoprotein heterodimer is located in the ER or
an ER-like compartment [3, 18]. The notation ManX,
where X ranges from 4 to 9 in the case of the observed
tryptic and chymotryptic glycopeptides, indicates that
X mannose residues are attached to the chitobiose core
(GlcNAc (1–4) GlcNAc). The glycans associated with
the HCV glycoprotein heterodimer have been previ-
ously characterized by HPLC and three species have
been observed: Man9, 8, and 7-GlcNAc2.
Whereas unmodified proteins can often be studied
by X-ray crystallography or nuclear magnetic resonance
spectroscopy, these methods may not provide reliable
structural information about the oligosaccharide moi-
eties of glycoproteins. Recently, mass spectrometry
(MS) using matrix assisted laser desorption/ionization
(MALDI) and/or electrospray ionization (ESI) [19–21]
have increasingly been used in glycobiology [22–24],
where no other structural technique can match MS forthe range of structural problems that can be addressed,
the complexity of samples that can be analyzed success-
fully, and the quantity of structural information that can
be obtained from subnanomolar amounts of material.
The main advantages of MS are its sensitivity, accuracy,
speed, and applicability to mixtures. The masses of
glycans on a protein can be determined either as free
oligosaccharides, after their release from the protein
and derivatization or while still attached to the peptide
backbone [25]. This mass information is indicative of
the sugar composition and can often be used to predict
sequences based on prior knowledge of biosynthetic
pathways. Sequencing of glycoproteins by MS requires
characteristic fragment ions (Hex, m/z 163.1 and Hex-
NAc, m/z 204.1) to be present in the mass spectra or
tandem MS (MS/MS) data [26]. Hence, data from MS
analyses of chemical and enzymatic degradations are
usually required to supplement molecular and frag-
ment ion information to define structural features such
as sugar type, branching and stereochemistry. Com-
plete structural characterization of a glycan, however,
also requires definition of branching, linkages, config-
urations, and the identification of similar sugar isomers.
Glycosylation analysis is recognized as one of the chal-
lenges in mass spectrometry and, therefore, to achieve this
goal, liquid chromatography and mass spectrometry
(LC-MS) methods are invaluable. The combination of LC
for the separation and MS/MS for the detection and
structural analysis of glycans and glycopeptides provides
detailed information at high sensitivity [27]. The most
convenient approach for the determination of the compo-
sition of the oligosaccharides present in a given protein
preparation regardless of their position on the protein
backbone(s) requires their release by enzymes (peptide
N-glycosidases F and A, endo-glycosidases) or by
chemical elimination procedures [28]. Typically, on-line
LC coupled to ESI MS followed by MS/MS are widely
applied to the analysis of oligosaccharide derivatives
[26, 28, 29]. Another approach for the study of glycop-
roteins is the combination of on-line (capillary electro-
phoresis) CE-ESI MS as it provides high-resolution,
sensitivity, and relatively short times of analysis [30, 31].
Identification of specific glycosylation sites requires a
lengthy process often involving trypsin digestion to
produce glycopeptides, separation of the glycopeptides
by high-performance liquid chromatography (HPLC),
and characterization of each fraction by MS with or
without enzymatic release to determine the oligosac-
charide and peptide structures of each fraction. Because
full scan mass spectra do not always yield unequivocal
structural information, tandem mass spectrometry is
often necessary to identify unique fragments that cor-
respond to the oligosaccharide moieties [32]. In addi-
tion, computer software such as GlycoMod [33] can be
used to easily and quickly determine the possible
N-glycan composition corresponding to experimentally
determined masses of trypsin generated glycopeptides.
In this study, the mass spectrometric characteriza-
tion of the glycopeptides from HCV E2 envelope gly-
rain H
italic
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be only of high mannose type. However, complex type
oligosaccharides, for which there has been little evi-
dence [34], were exclusively observed at two N-linked
sites, and their identity and heterogeneity were deter-
mined. This information should prove valuable in the
structural modeling of the E2 glycoprotein either en-
tirely in silico or based on eventual crystal structure of
the deglycosylated protein.
Experimental
Materials
HCV E2 envelope glycoprotein (recombinant) was pur-
chased from Austral Biologicals (San Ramon, CA).
Urea, dithiothreitol, iodoacetamide, 96% formic acid,
ammonium bicarbonate, and ethanol were purchased
from Sigma-Aldrich (St. Louis, MO). Sequencing grade
modified trypsin was obtained from Promega (Madi-
son, WI). Chymotrypsin was purchased from Roche
Diagnostics Corp. (Indianapolis, IN). Acetonitrile was
purchased from Caledon Laboratories, Ltd. (George-
town, Ontario). Purified water (17.8 M) was obtained
from an in-house Hydro Picopure 2 system. All chem-
icals were used without further purification unless
otherwise specified.
HCV E2 Sample Preparation
HCV E2 (10 g) expressed in Chinese hamster ovary
(CHO) cells was diluted in 75 L of buffer containing 5
M urea and 100 mM Tris (pH 7.8) (hydroxymethyl
aminomethane), and 100 mM dithiothreitol was added.
The protein was denatured for 1.5 h at 65 °C. Car-
boxymethylation was performed by adding 100 mM
iodoacetamide followed by incubation in the dark for
1 h at room temperature. The reaction was quenched by
adding 2.5 L dithiothreitol (100 mM) and incubated
for 15 min at room temperature. Before digestion, the
protein sample was purified using a Hewlett Packard
1100 HPLC system (Wilmington, DE) equipped with a
Vydak C4 column (4.6 mm i.d., 5 m particles) (Grace
Vydac, CA), a diode array detector, and a fraction
collector. Gradient elution was carried out with two
solvents: A: water, 0.1% formic acid; B: acetonitrile 90%,
water 10%, 0.1% formic acid. A linear gradient at 1
mL/min of 5% B–60% B over 50 min was used to purify
the proteins. Fractions were collected, lyophilized, and
redissolved in 50 L 60% acetonitrile, 0.1% formic acid
just before MALDI- time of flight (TOF) MS analysis.
In Solution Digestion of HCV E2
The HPLC fractions found by mass spectrometry to
contain the E2 glycoprotein were combined and lyoph-
ilized. The protein was redissolved in 50 L 50 mM
ammonium bicarbonate buffer pH 7.5, and trypsin was
added using an enzyme:substrate ratio of 1:50 anddigested overnight at 37 °C. A subsequent digestion
was performed in which chymotrypsin was added at an
enzyme: substrate ratio of 1:50. The reaction was al-
lowed to proceed overnight at 25 °C. After digestion the
reaction mixtures were lyophilized and were redis-
solved in 0.1% formic acid just prior the nanoLC/
MS/MS analysis.
Mass Spectrometry
MALDI-TOF mass spectra were acquired on a Voyager-
DE STR mass spectrometer (Applied Biosystems, Fra-
mingham, MA), equipped with a nitrogen laser ( 337
nm). The measurements were performed in the linear
positive ion mode. Samples (0.5 L) were spotted
onto a 100 sample stainless steel MALDI plate and
mixed on target with 0.5 L of a saturated solution of
-cyanohydroxycinnamic acid in 45:45:10 (vol:vol:vol)
water:ethanol:formic acid. The mass spectra were cali-
brated externally using a mixture of standard peptides
with a mass accuracy of greater than 0.01%. Data were
acquired in linear mode using an accelerating voltage of
23,000 V, a grid percentage of 80%, and a delay time of
300 ns.
NanoLC/MS/MS analyses were performed on a Wa-
ters Q-TOF Premier mass spectrometer equipped with a
nanoAcquity UPLC system and a NanoLockspray source
(Waters, Milford, MA). Separations were performed
using a 3 m nanoAcquity Atlantis column dC18 100
m  100 mm (Waters) at a flow rate of 300 nL/min. A
nanoAquity trapping column 5 m C18 180 m  200
mm (Waters) was positioned in-line with the analytical
column. Trapping of a 2 L aliquot of the digested
sample was performed for 3 min at 5 L/min flow rate.
Peptides were eluted using a linear gradient from 98%
A (water/0.1% formic acid (vol/vol)) and 2% B (aceto-
nitrile/0.1% formic acid (vol/vol)) to 95% B over 60
min. Mass spectrometer settings for MS analyses were
as follows: capillary voltage 3.5 kV, cone voltage 30 V,
collision energy 8.0 V, and scan range 200–2000 Da. The
tandem mass spectra were obtained in data dependant
acquisition mode, and a fixed range of collision energies
between 30 and 40 V were applied to ensure good
fragmentation of the glycopeptides. Peptides were iden-
tified by mass and charge measurement with in silico
digestion using the BioLynx Protein/Peptide Editor, fea-
ture of MassLynx v4.0 (Micromass, UK). For the unam-
biguous determination of glycosylated peptides, the
GlycoMod program, available on the internet as part of
the ExPASY suite of proteomics tools at http://www.
expasy.ch/tools/glycomod, was utilized [33].
Structural Images
To illustrate the structure of HCV E2, an existing
homology model made by Yagnik et al. [35] was used,
based on tick-borne encephalitis virus envelope gly-
coprotein E virus (TBEV). The crystal structure of
TBEV (1SVB) [36] was used to build the E2 homology
432 IACOB ET AL. J Am Soc Mass Spectrom 2008, 19, 428–444model, and the RASMOL program for molecular visual-
ization was utilized (http://www.umass.edu/microbio/
rasmol/ [37].
Results and Discussion
The E2 glycoprotein has been reported to contain pri-
marily high mannose glycans [15, 16]. To determine
specific glycan structures on E2, the intact native pro-
tein was first analyzed by MALDI-TOF MS. The amino
acid sequence of the glycoprotein E2 is shown in Figure
1b, with the numbering starting from Ala1 to Lys333
(which corresponds to the numbering Ala383 to Lys715
within the entire HCV polyprotein of reference strain H
GenBank access number AF009606) [38]. The 11 consen-
sus glycosylation sites on E2, highlighted in Figure 1b,
have been shown to be primarily occupied with high
mannose glycans [15]. As shown in Figure 2, the
MALDI-TOF mass spectrum of the intact glycosylated
protein contains broad ions that correspond in mass to
singly, doubly, and triply charged molecular ions. E2
has a theoretical molecular weight of 36.5 kDa, but the
observed mass of the singly charged ion in MALDI-TOF
mass spectrum was50 kDa, indicating a large amount
of N-linked glycosylation with extensive heterogeneity,
which hampers the ability to determine the exact mo-
lecular weight of the intact protein.
As alternatives to MALDI-TOF MS, methods such as
LC-MS can be applied for the study of glycoproteins
[23] by providing detailed information at high sensi-
tivity. Glycopeptides can be identified using LC-MS
of the enzymatic digestion mixture in the MS mode
based on characteristic ions arising from in-source
decay, which can be monitored by generating ex-
tracted ion chromatograms of these ions, for example,
Figure 2. MALDI-TOF mass spectrum (mass r
doubly, and triply charged molecular ions. The
glycosylation of E2.m/z 204.1 (protonated HexNAc) and m/z 366.1 (proton-
ated HexNAc1Hex1) [39–42]. A search of the MS/MS
data can be performed for these characteristic fragment
ions [43]. Another approach for the detection of the
glycopeptides in LC-MS analyses is through parent ion
detection (PID) [40]. We performed an initial experi-
ment in which the tryptic and chymotryptic digests
were analyzed on the Q-TOF using PID. Identification
of glycosylated peptides was accomplished using the
parent ion detection mode for specific sugar oxonium
ions (Hex, m/z 163.1 and HexNAc, m/z 204.1). A mass
spectrum at low collision energy (5 V) followed by one
at high collision energy (30 V) was acquired for each
peptide. The presence of specific sugar fragment ions in
the spectrum at high collision energy was diagnostic for
the presence of glycopeptides (data not shown).
The identities of the glycans attached at each N-
glycosylation site were determined from the LC-MS
analyses of the tryptic and chymotryptic digests of
reduced and alkylated E2 protein. From the LC/
MS/MS analysis of the tryptic digest, 4 of 11 consensus
N-linked sites were unambiguously determined. The
primary sequence of E2 contains only a few potential
trypsin cleavage sites; therefore, longer proteolytic frag-
ments containing multiple glycosylation sites were
formed. Consequently, these peptides were not ob-
served in the LC-MS analysis of the tryptic digest. To
elucidate the glycosylation pattern at the remaining
sites, chymotrypsin was used to generate shorter pro-
teolytic fragments that would contain a single glycosyl-
ation position within each peptide. Glycopeptides with
the same backbone structure containing different gly-
can moieties (site microheterogeneity) show a specific
pattern in ESI-MS [26]. Those glycopeptides ions form-
ing a charge envelope are separated by an absolute
10,000–100,000 Da) of HCV E2 showing singly,
adness of the peaks is due to of the extensiveange
bro
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mannose/hybrid type oligosaccharides. In addition,
collision activated dissociation (CAD) spectra of glyco-
peptides contain carbohydrate marker ions, such as at
m/z 163 (Hex), 204 (HexNAc), or 366 (HexHexNAc),
which simplify their identification if these masses are
extracted from the MS/MS total ion current. Different
batches of E2 glycoprotein were used in these experi-
ments and slight differences were noticed in the results,
especially in the relative abundance of some glycoforms
compared with others, as well as in the number of
attached mannose residues. However, similar glycosyl-
ation patterns of the protein were observed in all
experiments.
The N-linked glycosylation sites in E2 glycoprotein
contain a broad variety of high mannose glycans, rang-
ing from the minimal core structure (Man3) to, at most,
9 hexose residues attached to the trimannosyl chito-
biose moiety (Hex3Man9). It should be noted that the
relative abundances correspond to the abundance ratios
observed in the raw data, and that differences in
sensitivity and ionization efficiency were not consid-
ered. The relative abundance of the glycoforms con-
Table 1. Glycosylation sites and amino acid sequences of high m
digest of reduced and alkylated E2
Sitea Tryptic peptide Theor
N66
(N448)
65FNSSGCPER73b 2106
2268
2430
2592
2755
2917
3079
3241
3403
N194
(N576)
181VCGAPPCVIGGVGNNTLLCPTDCFRK206b 4401
4563
4725
N241
(N623)
233LWHYPCTINYTIFK246b 3071
3233
3395
3557
3719
3881
4043
4205
N263
(N645)
258LEAACNWTRGERCDLEDR275b 3676
3838
4000
4162
4324
4486
aThe numbers in parentheses represent the positions of the N-glycos
reference strain H (GenBank access number AF009606).
bRepresents a carboxymethylated cysteine residue.
cThe notation ManX indicates that X mannose residues are attached to
dThe relative abundance was determined from deconvoluted mass spectrum
to glycopeptides with the same amino acid sequence.tained at one N-linked site was determined from the
deconvoluted mass spectrum over the chromatographic
range containing the charge envelops of the ions for the
corresponding glycopeptides. The peptides determined
for each glycosylation site and the corresponding gly-
can populations are presented in Tables 1 and 2.
To corroborate our interpretation, the experimental
glycopeptide masses were submitted to GlycoMod, a
software tool used for determination of glycosylation
compositions from mass spectrometric data [33]. This
program compares the experimental mass of a glyco-
peptide to a list of precompiled masses of possible
monosaccharide compositions, taking into account the
possible peptides containing the N-X-S/T/C motif. For
example, the observed m/z of 1011.90 (corresponding to
a quadruply charged ion), was assigned to the tryptic
peptide 233–246, corresponding to the mass of 4043.66
Da, containing a carboxymethylated cysteine residue,
with an attached high mannose glycan of the composition
Hex2Man9GlcNAc2. Multiple monosaccharide composi-
tions, however, were proposed as possible matches
within a mass tolerance of 0.1 Da, in addition to the
assigned Hex2Man9GlcNAc2 structure, which has been
ose glycopeptides observed in LC-MS/MS analysis of a tryptic
Glycopeptide mass
Glycan
typec
Relative
abundancedl Observed
Mass accuracies
(ppm)
2106.763 16 Man 4 0.61
2268.800 22 Man 5 0.31
2430.855 20 Man 6 1
2592.910 17 Man 7 0.57
2754.980 10 Man 8 0.54
2917.015 15 Man 9 0.42
3079.045 21 Hex1Man9 0.38
3241.115 15 Hex2Man9 0.20
3403.181 10 Hex3Man9 0.15
4401.825 11 Man 7 0.6
4563.867 13 Man 8 1
4725.930 10 Man 9 0.44
3071.460 10 Man 5 0.54
3233.523 13 Man 6 1
3395.487 15 Man 7 0.65
3557.509 6 Man 8 0.38
3719.503 10 Man 9 0.52
3881.632 11 Hex1Man9 0.44
4043.664 5 Hex2Man9 0.70
4205.722 7 Hex3Man9 0.47
3676.497 8 Man 7 0.25
3838.589 17 Man 8 0.30
4000.600 7 Man 9 0.70
4162.650 6 Hex1Man9 1
4324.748 16 Hex2Man9 0.45
4486.758 8 Hex3Man9 0.65
n sites which correspond to the positions in the HCV polyprotein of
chitobiose core of each N-linked high mannose glycan.ann
etica
.798
.851
.904
.956
.008
.060
.112
.164
.216
.872
.925
.978
.428
.482
.435
.487
.539
.591
.644
.696
.469
.521
.573
.625
.677
.729
ylatio
the
over the mass range containing the glycopeptide ions corresponding
mass
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glycan structure, the MS/MS data of the [M  4H]4
ion of m/z 1011.90 was acquired. The fragment ions
observed by MS/MS confirmed the assigned glycan
composition Hex2Man9GlcNAc2 and the identity of the
Table 2. Glycosylation sites and amino acid sequences of high m
chymotryptic digest of reduced and alkylated E2
Sitea Chymotryptic peptide Theoretical
N35
(N417)
32INTNGSW38 1682.678
1844.731
2006.784
2168.837
2330.889
2492.942
2654.995
N66
(N448)
66NSSGCPERL74 2015.799
2177.852
2339.905
2501.957
2664.010
2826.063
N94
(N476)
88GPISYANGSGLDERPYCW105b 3743.481
3905.534
4067.587
4229.640
4391.692
N150
(N532)
148GANDTDVFVL157 2428.137
2590.031
2752.084
2914.137
3076.190
3238.243
N158
(N540)
156VLNNTRPPLGNWF168 2743.222
2905.275
3067.327
3229.380
3391.433
N174
(N556)
173MNSTGF178 1547.581
1709.634
1871.687
2033.740
2195.792
2357.845
2519.898
N241
(N623)
235HYPCTINY242 2225.855
2387.908
2549.950
2712.013
2874.066
N263
(N645)
251VGGVEHRLEAACNW264 2756.148
2918.201
3080.253
3242.306
3404.359
aThe numbers in parentheses represent the positions of the N-glycos
reference strain H (GenBank access number AF009606).
bRepresents a carboxymethylated cysteine residue.
cThe notation ManX indicates that X mannose residues are attached to
dThe relative abundance was determined from the deconvoluted
corresponding to glycopeptides with the same amino acid sequence.tryptic peptide 233–246 containing the glycosylationsite N241 (data not shown). The number of hexose
residues larger than nine indicates incomplete process-
ing of the precursor glycan. As mass spectrometry
using conventional CAD can not distinguish between
the isobaric monosaccharides mannose and glucose, the
ose glycopeptides observed in LC-MS/MS analysis of a
opeptide mass
Glycan
typec
Relative
abundancedbserved
Mass accuracy
(ppm)
682.676 1 Man 3 0.5
845.732 1 Man 4 0.95
006.774 4 Man 5 0.82
168.816 9 Man 6 1
330.873 7 Man 7 0.37
492.954 5 Man 8 0.25
655.016 8 Man 9 0.25
015.830 15 Man 4 0.85
177.829 10 Man 5 0.5
339.921 7 Man 6 1
501.953 2 Man 7 0.37
664.007 1 Man 8 0.36
826.069 2 Man 9 0.12
743.457 6 Man 8 0.17
905.519 4 Man 9 0.50
067.628 10 Hex1Man 9 1
229.704 15 Hex2Man 9 0.25
391.766 17 Hex3Man 9 0.22
428.156 8 Man 6 1
590.055 9 Man 7 0.45
752.131 17 Man 8 0.85
914.143 2 Man 9 0.42
076.207 6 Hex1Man 9 0.54
238.293 15 Hex2Man 9 0.52
743.241 7 Man 5 0.39
905.262 4 Man 6 1
067.361 11 Man 7 0.15
229.405 8 Man 8 0.10
391.451 5 Man 9 0.07
547.580 1 Man3 0.1
709.645 6 Man4 0.4
871.690 2 Man 5 0.62
033.732 4 Man 6 1
195.799 3 Man 7 0.30
357.844 1 Man 8 0.31
519.901 1 Man 9 0.27
225.835 9 Man 5 0.09
387.883 10 Man 6 1
549.960 4 Man 7 0.28
711.960 20 Man 8 0.19
874.069 1 Man 9 0.13
756.120 10 Man5 0.1
918.175 9 Man 6 1
080.230 7 Man 7 0.31
242.282 7 Man 8 0.33
404.325 10 Man 9 0.5
n sites which correspond to the positions in the HCV polyprotein of
chitobiose core of each N-linked high mannose glycan.
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435J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINare indicated as Hex1–3Man9 (Tables 1 and 2). In the
chymotryptic digest, the same site N241 was observed
containing only Man9 residues in total, and in both
digests the most abundant ion was the one correspond-
ing to Man6 structure (Tables 1 and 2). As explained
above, the differences in the number of mannose resi-
dues is caused by the slight differences between the E2
glycoprotein batches that were used. The tryptic glyco-
peptide 65–73, containing the glycosylation site N66
(N448), indicates the presence of high mannose species,
with a maximum of nine mannose residues attached to
the trimannosyl chitobiose core (Hex3Man9) and with
Man6 as the most abundant glycan. In the chymotryptic
digest, the peptide 66–74 containing the N66 site of
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The MS and MS/MS spectra of the chymotryptic
peptide 156–168 corresponding to the glycosylation site
N158 (N540) are presented in Figure 3. The high man-
nose species observed in the deconvoluted mass spec-
trum (Figure 3a) were assigned to glycopeptide 158–168
carrying five to nine mannose units attached to the
GlcNAc2 moiety (see Table 2). The notation ManX
indicates a high mannose glycan with X the number of
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436 IACOB ET AL. J Am Soc Mass Spectrom 2008, 19, 428–444sponding to the deconvoluted mass 2905.26 Da, was
determined from the CAD data of the doubly charged
precursor of m/z 1453.78 (Figure 3b). The precursor ion
represents the base peak in the MS/MS and the ob-
served fragment ions originate from the successive
neutral loss of hexoses from the nonreducing end of the
oligosaccharide. The glycan was fragmented down to
one GlcNAc moiety attached to the peptide backbone,
which was observed as both doubly (m/z 866.28) and
singly charged fragment ions (m/z 1731.56) in the spec-
trum. Another fragmentation pathway of the precursor
led to formation of singly protonated sugar ions, which
are characteristic of high mannose glycans. A single
backbone fragment ion observed at m/z 830.42 (y7),
which resulted from the cleavage of the amide bond
between Arg161 and Pro162, confirmed the identity of
the peptide as 156–168.
Figure 4. ESI-MS of chymotryptic peptide 173–
range 1500–3000, showing the glycopeptides wi
mannose glycans with composition fromMan3 to
(b) MS/MS of the precursor ion m/z 1017.85 (2
containing the Man6 glycan at the glycosylation
of glycan are indicated at the top (right). The p
peptide sequence. Filled circles represent Man
number in the bracket represents maximum of
core. The majority of the observed ions are singl
ions.The microheterogeneity of glycosylation site N174
(N556) observed in glycopeptide 173–178 is consistent
with a high mannose type glycan (Man3–9) and is
presented in Figure 4a. The masses in the deconvoluted
spectrum were assigned to glycopeptide 173–178 con-
taining glycans with a length ranging from Man3 to
Man9. The Man5 and Man6 are the most abundant
populations, followed by Man4, Man7, Man8, and
Man9, which are almost equally represented. The tan-
dem mass spectrum of the doubly charged ion of m/z
1017.85, corresponding to glycopeptide 173–178, which
contains a Man6 glycan is presented in Figure 4b. This
precursor ion also fragmented to the intact peptide
backbone (m/z 859.66) with a GlcNAcmoiety attached at
site N174. Interestingly, the protonated peptide ion of
m/z 656.66 resulted from the complete loss of the
oligosaccharide by glycosidic bond cleavage between
(a) Deconvoluted mass spectrum over the mass
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9. The open diamonds represent unrelated ions.
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437J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINthe sugar and the Asn side chain. Unlike the other
MS/MS data, a large number of specific backbone
cleavages were observed (b3, b4, b5, and y4) and the
peptide backbone could be almost completely assigned
based on this spectrum (Figure 4b). In addition, back-
bone fragments still containing one or two GlcNAc
units were abundant. This fragmentation pattern and
the data discussed above suggest that the presence of
backbone fragmentation may be dependent on the
amino acid sequence and length of the peptide contain-
ing the sugar on the position of the glycosylation site
within the peptide backbone, or on a combination of
these factors.
For the tryptic peptide 181–206 containing the glyco-
sylation site N194 (N576), a maximum of Man9 residues
were observed, with Man8 being the most abundant
ion. In the chymotryptic digest the peptide 191–204
Figure 5. (a) Deconvoluted mass spectrum ove
tides with the amino acid sequence 251–264 cont
Man5 to Man9. (b) MS/MS of the precursor io
glycopeptide 251–264 containing the Man9 glyca
of the glycopeptide and the structure of the glyca
difference of 81 u between doubly charged frag
Filled circles represent Man residues; open recta
represents maximum of Man residues attached
charged ions formed by fragmentation of the glycancontaining the same site of glycosylation was seen
having the same number of mannoses residues attached
to this N-linked site (data not shown).
The deconvoluted mass spectrum of the region of the
chromatogram where glycoforms of the peptide 251–
264 (N645) appeared is presented in Figure 5a. These
data indicate the presence of high mannose glycans
with a minimum Man5 and maximum Man9 composi-
tion. Man6 is the most abundant among these species.
The tandem mass spectrum of the triply charged ion of
m/z 1135.77 (Figure 5b) is consistent with the proposed
glycan composition (Man9) for the peptide 251–264. The
major fragmentation pathway arises from successive
cleavage of the monosaccharides from the nonreducing
end of the glycan. The composition of the glycan was
deduced from the mass difference between these frag-
ments. The doubly charged molecular peptide ion of
mass range 2500–4000, showing the glycopep-
g high mannose glycans with composition from
z 1135.77 (3) corresponding to chymotryptic
position N263 (N645). The amino acid sequence
indicated at the top (right). The successive mass
t ions is indicative for a high mannose glycan.
s represent GlcNAc. The number in the bracket
the glycosylation site. The star denotes singlyr the
ainin
n m/
n at
n are
men
ngle
toand charge reduction of the precursor ion.
438 IACOB ET AL. J Am Soc Mass Spectrom 2008, 19, 428–444m/z 770.83 is less abundant, while the ion of m/z 872.37,
assigned to the peptide 251–264 with a single GlcNAc
moiety attached at N263, represents the most abundant
ion (Figure 5b). This N-linked site showed slight differ-
ences in the number of attached mannoses, where up to
Hex3Man9 were identified for N263 in the tryptic pep-
tide 258–275, compared with Man9 that were observed
in the chymotryptic peptide 251–264. This high number
of hexoses suggests incomplete processing of the pre-
cursor glycan. As discussed above, these results are due
to the differences in the protein batches that were used
(Tables 1 and 2).
The deconvoluted mass spectrum of the region of the
chromatogram where glycopeptides 48–58 and 22–36,
and their glycoforms containing the N-linked sites N48
and N35, respectively elute, is shown in Figure 6a. For
the site N35, a maximum of Man9 residues was ob-
Figure 6. (a) Deconvoluted mass spectrum
microheterogeneity of the glycopeptides 48–58
ation are underlined. For the clarity of the figure,
48–58 are schematically represented. (b) MS/MS
ing to the anomalous chymotryptic glycopeptide
(at the top, right) attached to the N48 (N430)
rectangles represent GlcNAc, and the filled tria
bracket indicates the additional presence of a
glycopeptide fragment ions resulted from the fra
precursor.served, with Man4, Man5, and Man6 being the most
abundant species. The deconvoluted masses were as-
signed to each peptide containing different glycan
structures. The mass spectrum was deconvoluted over
the entire range containing the charge envelops of
multiply charged ions, for the corresponding glycopep-
tides. The identity of these species was confirmed by
MS/MS of the corresponding multiply charged ions
(data not shown). Small amounts of the species Man1
and Man2 were observed in the spectrum, indicating
that, to some extent, the glycopeptides underwent in-
source decomposition. For the peptide 48–58, complex
type glycans were exclusively observed at site N48
(N430). In the deconvoluted mass spectrum (Figure 6a),
ions for these glycoforms with masses at m/z 2198.90,
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439J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINto the sugarN-acetylglucosamine, therefore indicating the
presence of zero, one, or two terminal GlcNAc residues.
This was assigned as N-acetylglucosamine because this
monosaccharide is expected to elongate the Man3 core
structure in complex N-linked glycans. The identity
of the peptide observed with this sugar moiety and
the composition of the glycan were determined from the
MS/MS of the doubly charged precursor of m/z 1201.95
(Figure 6b). Singly charged fragment ions separated by
146 u clearly indicate the presence of fucose (Fuc) attached
at the first GlcNAc residue of the Man3GlcNAc2 core. The
singly charged ion of m/z 1510.68 corresponds in mass to
amino acids 48–58, plus a GlcNAcFuc rest. The ion of m/z
1364.68 corresponds in mass to residues 48–58 with a
single GlcNAc. Two series of fragment ions were
observed in the MS/MS spectrum (Figure 6b): one
series is composed of doubly charged fragment ions
that result from the successive neutral loss of
monosaccharides from the nonreducing end. The
other series of ions are formed by charge reduction
of the precursor ion. These data are consistent with
the glycan structure GlcNAcFuc–Man3GlcNAc2 at the
site N48. The deconvoluted masses of m/z 2198.90
and 2605.08 correspond in mass to residues 4–58 plus
the complex type glycans Fuc–Man3GlcNAc2 and
GlcNAc2Fuc–Man3GlcNAc2, respectively (see Figure 6a
and Table 3). Interestingly, these glycopeptides could
result from anomalous chymotrypsin activity, which
cleaved after glycine residues in both cases instead of
residues specific for this enzyme. However, in the
absence of backbone fragmentation, the observed mass
of the peptide by itself cannot rule out the possibility
that cleavage at other residues occurred; the peptide
QHKFNSSGCP, bearing the site N66 (N448) and with
the cysteine alkylated, has a mass (1160.50) similar to
peptide 48–58 (1160.55) and, thus, could also represent
a plausible candidate. Cleavage after proline, however,
is very uncommon for all serine proteases, irrespective
Table 3. Glycosylation sites and amino acid sequences of comp
chymotryptic digest of reduced and alkylated E2
Sitea Chymotryptic peptide
Glycopep
Theoretical Observed
N41
(N423)
39HINSTAL45 1849.794 1849.786
1995.852 1995.831
2132.873 2132.860
1970.820 1970.811
1808.767 1808.769
1646.714 1647.711
N48
(N430)
48NESLNTGWLAG58b 2198.921 2198.902
2402.001 2401.984
2605.080 2605.071
aThe numbers in parentheses represent the positions of the N-glycos
reference strain H (GenBank access number AF009606).
bAnomalous chymotryptic cleavage sites.
cThe notation ManX indicates that X mannose residues are attached to
notations indicate complex type glycans.
dThe relative abundance was determined from the deconvoluted mass
corresponding to glycopeptides with the same amino acid sequence.of their specificity, and this plus the observed mass
error argues against (but does not disprove) assignment
of the peptide as QHKFNSSGCP. There is also the
possibility that a peptide modification or protein muta-
tion occurred, as E2 is a viral recombinant protein, and
that, instead of cleavage after glycine, this ion may arise
from an unidentified amino acid sequence that contains
multiple mutations/modifications. No evidence, how-
ever, for the presence of mutations was observed in the
rest of our data. Therefore, the most likely origin of this
ion is that it is attributable to a peptide formed by a
nonspecific cleavage occurring after glycine, as chymo-
trypsin is less specific than trypsin. Because complex
types N-glycans have a well defined sugar composi-
tion; this enables the identification of the peptide
containing this type of glycan from the MS/MS data
(i.e., the fragment containing a single GlcNAc moiety).
The backbone fragment with the amino acid sequence
48–58 was the only peptide that matched the mass of
these glycopeptide fragment ions. Usually chymotryp-
sin cleaves the protein backbone after aromatic amino
acids at higher rates than after other amino acids, but
under different circumstances (glycan type, conforma-
tion of the protein) it also may cleave other amino acids
[44]. These data show that the presence of the glycan
moieties attached to E2 can alter the specificity of
chymotrypsin. The formation of glycopeptides from
nonspecific proteolytic cleavages complicates the as-
signment of the N-linked sites and of the corresponding
glycan structures using MS data alone.
In addition to N48, complex type glycans were
determined for the site N41 (N423), observed in peptide
39–45 (Table 3). The sugar composition of the complex
type glycans was determined from the MS/MS data of
the glycopeptides observed as doubly charged ions of
m/z 926.38 (1849.78 Da) as: GlcNAc–Man3GlcNAc2 and
m/z 999.39 (1995.83) as GlcNAcFuc–Man3GlcNAc2, re-
spectively, (data not shown). High mannose type oligo-
pe glycopeptides observed in LC- MS/MS analysis of a
mass
Glycan typec
Relative
abundancedMass accuracy (ppm)
4 Man3-GlcNAc 0.28
10 Man3-GlcNAc-Fuc 1
6 Man 6 0.80
4 Man 5 0.88
1 Man 4 0.20
2 Man 3 0.10
8 Man3-Fuc 0.18
7 Man3-GlcNAc-Fuc 1
4 Man3-GlcNAc2-Fuc 0.29
n sites which correspond to the positions in the HCV polyprotein of
hitobiose core of each N-linked high mannose glycan. The rest of thelex-ty
tide
ylatio
the cspectrum over the mass range containing the glycopeptide ions
440 IACOB ET AL. J Am Soc Mass Spectrom 2008, 19, 428–444saccharides ranging from Man3 to Man6 were also
observed at the site N41 (peptide 39–45, Table 3) and
the corresponding glycopeptides eluted slightly later
than those carrying the complex type glycans. Interest-
ingly, for both sites containing complex type glycans,
the Man3GlcNAcFuc species is the most abundant ion.
Regarding the sugar composition, we may say that
these are not mature complex type glycans. This is the
first time that complex type glycans were positively
identified on the E2 glycoprotein. Although it has not
been reported that these complex glycans transit through
the medial Golgi, they are possibly not sufficiently long to
develop into mature structures, and thereby are immedi-
ately translocated into the ER compartment.
Tables 1, 2, and 3 summarize the glycosylation sites
identified after tryptic and chymotryptic digestions,
indicating the position of glycosylation and the ob-
served glycopeptides, as well as the glycopeptide neu-
tral masses. Using GlycoMod software the E2 glycopep-
tides resulted from both chymotrypsin as well as
trypsin digests with a mass accuracy of 0.1 Da were
identified. Multiple monosaccharide compositions were
proposed as possible matches in some instances, and
the correct glycan structure was determined from
MS/MS analyses. The data identification, however, was
unreliable when nonspecific chymotryptic cleavages
occurred, so that manual interpretation of the MS/MS
data was mandatory to ascertain the correct amino acid
sequence of the glycopeptides and the composition of
the attached glycans. As presented in Table 2, short
glycopeptides were observed (e.g., 32–38 or 173–178)
eluting from the C18 column. From our experiments, it
does not appear that short glycopeptides were lost
during the trapping process, however, this fact cannot
be absolutely excluded.
The envelope proteins play a major role in a virus life
cycle. Envelope proteins are involved in viral entry into
the cell by binding to a receptor present on the host cell
and inducing fusion between the viral envelope and the
membrane of the host cell [16]. The E2 protein is heavily
glycosylated with 11 potential sites of glycosylation.
Nine of these 11 sites are highly conserved, suggesting
that the glycosylation may play an essential role in
some biological functions or conformation of the glyco-
protein [15]. In the early secretory pathway, the glycans
play a role in protein folding and in certain sorting
events [17]. It is known that during glycosylation of a
protein, a precursor oligosaccharide composed of
GlcNAc, Man, and glucose (Glc), with the composition
Glc3Man9GlcNAc2, is transferred to nascent proteins in
the ER in a cotranslational event [17]. The diversity of
these N-linked oligosaccharide structures on mature
glycoproteins arises from major modification of this
precursor structure, which occurs post-translationally.
While still in the ER, the glucose residues are quickly
removed from the oligosaccharides of most glycopro-
teins. This process continues in the Golgi apparatus
and, thus, glucose is not observed on the mature
glycoprotein [3]. From our data, peptides with levels ofmannosylation higher than Man9 were detected, indi-
cating incomplete processing. Incomplete processing of
glycans might be a function of protein processing while
still in the ER compartment, with a high level of
mannosylation being present in HCV in its natural
setting. Incomplete processing in which the hexose resi-
dues in excess of the expected Man9 maximum are glu-
coses could also be explained by the folding of the protein,
which might alter the accessibility of these glycans to the
processing by glucosidases and mannosidases. The hy-
pothesis that steric hindrance interferes with glycan
processing is consistent with our hypothesis that the
glycans play a significant role in stabilization of protein
tertiary structure. In the low-energy CID experiments
involved for the structural characterization of E2 glyco-
peptides, one cannot differentiate between isobaric
mannose and glucose structures; consequently the gly-
cans observed as having a number of hexoses higher
than Man9 are depicted as Hex1–3Man9.
To accurately characterize a glycoprotein, mass spec-
trometry has proven to have a tremendous ability to
identify the type of glycans as well as the sites of
glycosylation on a protein. For example, we have used
a combination of MALDI-TOF and LC followed by
nanoLC/MS/MS to characterize the glycan structures
attached to the human immunodeficiency virus (HIV)
gp120 glycoprotein, and high mannose glycans and hy-
brid glycans were found attached to the protein [32, 45].
Although LC-MS analysis of released glycans may
provide a detailed picture of the structure of the glycans
derived from a protein or any complex protein mixture,
information on the original attachment sites of the
glycans and the underlying proteins is lost. This critical
information can either be obtained by LC-MS analysis
of the remaining peptides after glycan release based on
Asn to Asp conversion but cannot connect specific
glycans to specific sites or by the direct analysis of
glycopeptides, which provides the connection between
glycan type and location.
In this present paper, the MS/MS spectra of high
mannose oligosaccharides were readily differentiated
from those of hybrid/complex type and provided im-
mediate information about the glycans on E2. Large
glycopeptides with a high sugar to peptide ratio are
expected to be highly sensitive to in-source fragmenta-
tion by glycosidic bond cleavage and, therefore, need
special analysis conditions. Furthermore, efficient for-
mation of multiply charged ions of glycopeptides is
crucial for their detection within the mass range of the
instrument as well as for high-resolution of the isotopic
pattern. The major collision induced dissociation frag-
mentation pathway of high mannose glycan containing
peptides can be characterized by the successive loss of
the sugar moieties from the nonreducing end of the
glycan, thereby generating a series of ions containing
the peptide backbone and the remaining sugars at-
tached at the reducing end [26]. In addition to the losses
from the nonreducing end, tandem mass spectra of com-
plex type glycans contain at least one additional series of
441J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINions that result from the initial loss of the (16) linked
fucose from the first GlcNAc residue of the trimannosyl
chitobiose core. Although they are not usually observed
in the CAD spectra of protonated glycopeptides, ions
due to backbone cleavages along the amino acid chain,
commonly with complete or partial loss of the glycan
chain, have also been observed in the MS/MS spectra.
These data allow for the identification of the peptide
that contain the glycans, as well as the precise location
of the glycan. The observation of amino acid backbone
cleavages may depend on several factors: (1) the amino
acid sequence; (2) the number of amino acid residues
contained in a glycopeptide; (3) the position of the
sugar chain within the glycopeptide or, (4) a combina-
tion of these factors.
To successfully investigate the glycans and their role
in the structure and function of the E2 protein, a
structure of the glycoprotein or, at a minimum, a
working model of the glycoprotein is required. To date
there is no crystal structure available for the E2 protein.
Therefore, the homology model of E2 was based on the
tick-borne encephalitis virus envelope glycoprotein E
virus (TBEV). Because of that, it would be reasonable to
assume that its physical relationship to the viral mem-
brane would also be similar. Previous studies showed
that Flavivirus envelope glycoprotein E from TBEV
shows functional similarity to E2 [36] and these proteins
are similar from the point of view of the parameters in
these fold recognition structures [35]. Moreover, the
organization of E2 into multiple antigenic domains has
similarities to the large envelope glycoprotein E on
TBEV and also with the envelope protein E1 from
Semliki Forest virus, an alphavirus [46] having similar
structural and functional properties [47]. Thus, to map
the location of the glycans on a model structure, the
TBEV structure (1SVB) was selected as a good candi-
date for a homology model of E2 [36]. These viruses
undergo structural rearrangements at low pH environ-
ments, which hypothetically lead to the exposure of
initially buried hydrophobic residues, and this process
is believed to be part of an endocytosis entry pathway
[47]. Therefore, a published homology model for the E2
protein based on the TBEV structure was employed as
a working model [35].
The location of the glycans on the E2 was thus
mapped to the homology model and is presented in
Figure 7. The two complex type glycans that were
newly identified by mass spectrometry are represented
in green. The N41 (N423) site, previously described as
buried in this model [35] rather than surface exposed, is
located in a region rich in -sheet structural elements.
By comparison to N41, N48 (N430) is mainly surface
exposed, and located on the opposite site of the mole-
cule, being nearly parallel to the location of N41. Based
on a hydrophobicity plot, Yagnik et al. predicted that
the region between amino acids 35–55 (418–438) (thus
encompassing the two complex type glycans) is hydro-
phobic and mainly surrounded by -sheet structures
[35]. The distance between the two glycosylation sites inthis model is 19Å. This region of the protein 35–55 has
not been previously characterized to have a specific
biological function, but considering the high -sheet
content, one might speculate that it is involved in the
folding process of the E2 protein, maybe implicating the
complex type glycans that are located in its vicinity,
which may have an impact on the 3-D structure and
folding of the protein. It has been previously reported
that modification of the complex type glycans by sialy-
lation could affect the potential biological activity of the
virus, possibly by reducing the infectivity of the pri-
mate lentivirus [48]. Furthermore, in the case of gp120,
it was reported that the removal of the fucose associated
with sialylated glycans changed the protein conforma-
tion, most likely by exposing epitopes that were previ-
ously buried [49]. It has been demonstrated that the
N-linked glycans of the HIV envelope glycoprotein
limit its immunogenicity and restrict binding of certain
antibodies to their epitopes on the virion surface [50].
Viral envelope proteins usually contain N-linked
glycans, which can play a major role in their folding,
entry functions, or in modulating the immune response
[50, 51]. Previous studies indicated that mutation of
some glycosylation sites in the HCV envelope glycop-
roteins can reduce or abolish HCV pseudoparticles
(HCVpp) infectivity without affecting incorporation of
the glycoproteins into the particles [16], possibly by
changes in the local conformation of the antibody
recognition sites. Moreover, E2 N-linked glycans at
position N41 (N423) and N66 (N448) were reported as
high mannose and have been shown to be essential for
the entry functions of HCV envelope glycoproteins [16].
Interestingly, N41 (N423) is one of the glycan sites that
was identified here as containing both complex type
glycans as well as high mannose type glycans, indicat-
ing the microheterogeneity of this specific site. Based on
these observations, one might predict that the presence
of this glycan at the N41 (N423) site is essential for
proper folding of the protein as well as for antibody
recognition on E2. In addition, a recent study showed
that the loss of glycosylation at N41 (N423) site leads to
noncovalent heterodimer formation as well as CD81
binding, indicating that the removal of a large sugar
moiety leads to better exposure of the CD81 binding site
[52]. Furthermore, they observed reduction in HCVpp
infectivity upon glycan removal. Glycosylations at sites
N35 (N417), N94 (N476), N150 (N532) and N263 (N645)
have also been shown to modulate HCVpp entry.
Furthermore, N174 (N556) and N241 (N623) were indi-
cated to have a direct effect on protein folding [16]. The
presence of a large, polar oligosaccharide is indeed
known to affect protein folding by orienting polypep-
tide segments toward the surfaces of the protein do-
mains [17, 53]. Moreover, to establish the natural prop-
erties of the virus, lectin-binding assays were
performed by Sato et al. to characterize the glycan
moiety on the surface of HCV particles recovered from
sera of infected patients [34]. This study suggested that
the envelope glycoproteins E1 and E2 of HCV might
442 IACOB ET AL. J Am Soc Mass Spectrom 2008, 19, 428–444contain complex type glycans, and their results also
indicated that the N-linked glycans are present on the
surface of native virions of HCV [34]. These authors
also postulated that the selectivity of HCV and hepatitis
B virus (HBV) in binding different lectins is related to
the nature of the carbohydrate structures on the virion
surface. Using different types of lectins and based on
their binding efficiency it was concluded that these
viruses would contain complex type sugar chains and
that the sugar moieties present on HCV virions are very
similar to those for HBV. However, no further evidence
for the presence and location of complex type glycans
on E2 was presented. Although no possible biological
function of these complex type glycans was reported,
we hypothesize that there may be a correlation between
the types of N-linked glycans and the structure and
function of the E2 protein, but this hypothesis remains
Figure 7. HCV E2 homology model based on th
E (TBEV) structure (PDB id: 1SVB): (a) Cartoon re
of the glycans attached to the protein. The nine si
mannose type sugars are highlighted in magen
glycans attached are shown in green. (b) Anot
filling representation. The same colors as descri
glycans on E2.to be investigated in a future study.Conclusions
The mass spectrometric characterization of the glyco-
peptides from HCV E2 envelope glycoprotein using
nanoLC/MS/MS is reported. Using tandem mass spec-
trometry the glycan moieties associated with all 11
consensus sites of glycosylation on E2 were clearly
characterized. These mass spectrometric results are
consistent with previously reported high mannose type
N-glycans. More importantly, in addition to high man-
nose glycans, complex type oligosaccharides were iden-
tified at two N-linked sites and their identity was
established from MS/MS data. These complex type
glycans were observed at positions N41 (N423) and N48
(N430). These data show the unambiguous mass spec-
trometric characterization of the glycans attached to the
E2 protein. To summarize, it is our hope that these
borne encephalitis virus envelope glycoprotein
entation of E2 glycoprotein showing the location
f glycosylation found to have attached only high
nd the two sites found to have complex type
iew of the E2 glycoprotein illustrated in space
above were used to indicate the location of thee tick
pres
tes o
ta, a
her v
bedresults may lead to a better understanding of the
443J Am Soc Mass Spectrom 2008, 19, 428–444 MS DETERMINATION OF GLYCANS OF HCV E2 PROTEINhepatitis C virus envelope E2 protein processing, and
may finally help in the elucidation of the structure of
the protein.
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